Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.

Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP.

Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.

2.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA.

Oncogene. 2019 Mar;38(13):2241-2262. doi: 10.1038/s41388-018-0567-7. Epub 2018 Nov 26.

3.

Correction: Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Nycz BT, Dominguez SR, Friedman D, Hilden JM, Ir D, Robertson CE, Frank DN.

PLoS One. 2018 May 10;13(5):e0197530. doi: 10.1371/journal.pone.0197530. eCollection 2018.

4.

Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Nycz BT, Dominguez SR, Friedman D, Hilden JM, Ir D, Robertson CE, Frank DN.

PLoS One. 2018 Jan 12;13(1):e0191232. doi: 10.1371/journal.pone.0191232. eCollection 2018. Erratum in: PLoS One. 2018 May 10;13(5):e0197530.

5.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.

Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.

6.

The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2-Implications for fellowship training.

Leavey PJ, Hilden JM, Matthews D, Dandoy C, Badawy SM, Shah M, Wayne AS, Hord J; American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26765. Epub 2017 Oct 25.

PMID:
29068565
7.

Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report.

Rogers AE, Eisenman KM, Dolan SA, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW, Dominguez SR.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26254. Epub 2016 Sep 12.

PMID:
27616655
8.

Early career mentoring through the American Society of Pediatric Hematology/Oncology: Lessons learned from a pilot program.

Badawy SM, Black V, Meier ER, Myers KC, Pinkney K, Hastings C, Hilden JM, Zweidler-McKay P, Stork LC, Johnson TS, Vaiselbuh SR.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26252. Epub 2016 Sep 12.

9.

Investigation of a cluster of Clostridium difficile infections in a pediatric oncology setting.

Dantes R, Epson EE, Dominguez SR, Dolan S, Wang F, Hurst A, Parker SK, Johnston H, West K, Anderson L, Rasheed JK, Moulton-Meissner H, Noble-Wang J, Limbago B, Dowell E, Hilden JM, Guh A, Pollack LA, Gould CV.

Am J Infect Control. 2016 Feb;44(2):138-45. doi: 10.1016/j.ajic.2015.09.004. Epub 2015 Oct 23.

PMID:
26601705
10.

A multidisciplinary approach to the management of anterior mediastinal masses in children.

Acker SN, Linton J, Tan GM, Garrington TP, Bruny J, Hilden JM, Hoffman LM, Partrick DA.

J Pediatr Surg. 2015 May;50(5):875-8. doi: 10.1016/j.jpedsurg.2014.09.054. Epub 2014 Oct 3.

PMID:
25783332
11.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P.

Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc.25311. Epub 2014 Nov 18.

12.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

13.

High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients.

Dominguez SR, Dolan SA, West K, Dantes RB, Epson E, Friedman D, Littlehorn CA, Arms LE, Walton K, Servetar E, Frank DN, Kotter CV, Dowell E, Gould CV, Hilden JM, Todd JK.

Clin Infect Dis. 2014 Aug 1;59(3):401-3. doi: 10.1093/cid/ciu302. Epub 2014 Apr 29.

PMID:
24785235
14.

Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report.

Valentine MC, Linabery AM, Chasnoff S, Hughes AE, Mallaney C, Sanchez N, Giacalone J, Heerema NA, Hilden JM, Spector LG, Ross JA, Druley TE.

Leukemia. 2014 Jun;28(6):1235-41. doi: 10.1038/leu.2013.367. Epub 2013 Dec 4.

15.

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.

Blood. 2013 Apr 4;121(14):2689-703. doi: 10.1182/blood-2012-04-425033. Epub 2013 Feb 7.

16.

Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.

Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, Carroll WL, Camitta B, Dreyer ZE.

Pediatr Blood Cancer. 2012 Nov;59(5):834-9. doi: 10.1002/pbc.24132. Epub 2012 Apr 5.

17.

Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.

Ross JA, Linabery AM, Blommer CN, Langer EK, Spector LG, Hilden JM, Heerema NA, Radloff GA, Tower RL, Davies SM.

Pediatr Blood Cancer. 2013 Jan;60(1):31-4. doi: 10.1002/pbc.24131. Epub 2012 Mar 15.

18.

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.

Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS.

Cancer. 2012 Oct 1;118(19):4806-14. doi: 10.1002/cncr.27484. Epub 2012 Mar 5.

19.

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Stam RW, Valsecchi MG, Pieters R, Heerema NA, Hilden JM, Felix CA, Reaman GH, Camitta B, Winick N, Carroll WL, Dreyer ZE, Hunger SP, Willman CL.

Blood. 2012 Feb 23;119(8):1872-81. doi: 10.1182/blood-2011-10-382861. Epub 2011 Dec 30.

20.

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO.

Blood. 2011 Dec 22;118(26):6752-9; quiz 6996. doi: 10.1182/blood-2011-04-350017. Epub 2011 Aug 17.

21.

MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.

Sam TN, Kersey JH, Linabery AM, Johnson KJ, Heerema NA, Hilden JM, Davies SM, Reaman GH, Ross JA.

Pediatr Blood Cancer. 2012 Jun;58(6):836-9. doi: 10.1002/pbc.23274. Epub 2011 Jul 28.

22.

Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group.

Slater ME, Linabery AM, Spector LG, Johnson KJ, Hilden JM, Heerema NA, Robison LL, Ross JA.

Cancer Causes Control. 2011 Aug;22(8):1197-204. doi: 10.1007/s10552-011-9798-4. Epub 2011 Jun 21.

23.

Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer.

Dussel V, Bona K, Heath JA, Hilden JM, Weeks JC, Wolfe J.

J Clin Oncol. 2011 Mar 10;29(8):1007-13. doi: 10.1200/JCO.2009.27.8960. Epub 2011 Jan 4.

24.

Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.

Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M, Hilden JM, Heerema NA, Sanders JE, McGlennen R, Willman CL, Carroll AJ, Behm F, Smith FO, Woods WG, Godder K, Reaman GH.

J Clin Oncol. 2011 Jan 10;29(2):214-22. doi: 10.1200/JCO.2009.26.8938. Epub 2010 Dec 6.

25.

Maternal vitamin and iron supplementation and risk of infant leukaemia: a report from the Children's Oncology Group.

Linabery AM, Puumala SE, Hilden JM, Davies SM, Heerema NA, Roesler MA, Ross JA; Children's Oncology Group.

Br J Cancer. 2010 Nov 23;103(11):1724-8. doi: 10.1038/sj.bjc.6605957. Epub 2010 Oct 26.

26.

Fatigue in children with cancer at the end of life.

Ullrich CK, Dussel V, Hilden JM, Sheaffer JW, Moore CL, Berde CB, Wolfe J.

J Pain Symptom Manage. 2010 Oct;40(4):483-94. doi: 10.1016/j.jpainsymman.2010.02.020. Epub 2010 Aug 1.

PMID:
20678889
27.

Infant leukemia and congenital abnormalities: a Children's Oncology Group study.

Johnson KJ, Roesler MA, Linabery AM, Hilden JM, Davies SM, Ross JA.

Pediatr Blood Cancer. 2010 Jul 15;55(1):95-9. doi: 10.1002/pbc.22495.

28.

End-of-life experience of children undergoing stem cell transplantation for malignancy: parent and provider perspectives and patterns of care.

Ullrich CK, Dussel V, Hilden JM, Sheaffer JW, Lehmann L, Wolfe J.

Blood. 2010 May 13;115(19):3879-85. doi: 10.1182/blood-2009-10-250225. Epub 2010 Mar 12.

29.

Considerations about hastening death among parents of children who die of cancer.

Dussel V, Joffe S, Hilden JM, Watterson-Schaeffer J, Weeks JC, Wolfe J.

Arch Pediatr Adolesc Med. 2010 Mar;164(3):231-7. doi: 10.1001/archpediatrics.2009.295.

30.

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.

Bhat R, Malinge S, Gamis AS, Sorrell AD, Hilden JM, Ketterling RP, Paietta E, Tallman MS, Crispino JD.

Leukemia. 2009 Nov;23(11):2159-60. doi: 10.1038/leu.2009.159. Epub 2009 Aug 6. No abstract available.

PMID:
19657363
31.

Parents' views of cancer-directed therapy for children with no realistic chance for cure.

Mack JW, Joffe S, Hilden JM, Watterson J, Moore C, Weeks JC, Wolfe J.

J Clin Oncol. 2008 Oct 10;26(29):4759-64. doi: 10.1200/JCO.2007.15.6059. Epub 2008 Sep 8.

32.

Looking beyond where children die: determinants and effects of planning a child's location of death.

Dussel V, Kreicbergs U, Hilden JM, Watterson J, Moore C, Turner BG, Weeks JC, Wolfe J.

J Pain Symptom Manage. 2009 Jan;37(1):33-43. doi: 10.1016/j.jpainsymman.2007.12.017. Epub 2008 Jun 6.

33.

The ABCs of infant leukemia.

Zweidler-McKay PA, Hilden JM.

Curr Probl Pediatr Adolesc Health Care. 2008 Mar;38(3):78-94. doi: 10.1016/j.cppeds.2007.12.001. Review. No abstract available.

PMID:
18279790
34.

Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.

Heald B, Hilden JM, Zbuk K, Norton A, Vyas P, Theil KS, Eng C.

Nat Clin Pract Oncol. 2007 Jul;4(7):433-8.

PMID:
17597708
35.

Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group.

Spector LG, Davies SM, Robison LL, Hilden JM, Roesler M, Ross JA.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):128-34.

36.

Program interventions for children at the end of life and their siblings.

Duncan J, Joselow M, Hilden JM.

Child Adolesc Psychiatr Clin N Am. 2006 Jul;15(3):739-58.

PMID:
16797447
37.

From cure to palliation: managing the transition.

Hutton N, Jones B, Hilden JM.

Child Adolesc Psychiatr Clin N Am. 2006 Jul;15(3):575-84, vii. Review.

PMID:
16797439
38.

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen R, Smith FO, Woods WG, Salzer WL, Johnstone HS, Dreyer Z, Reaman GH; Children's Oncology Group.

Blood. 2006 Jul 15;108(2):441-51. Epub 2006 Mar 23.

39.

Complementary and alternative medicine in pediatric oncology: availability and institutional policies in Canada--a report from the Children's Oncology Group.

Johnston DL, Nagel K, O'Halloran C, Sencer SF, Kelly KM, Friebert S, Hilden JM, Friedman DL; Children's Oncology Group.

Pediatr Blood Cancer. 2006 Dec;47(7):955-8.

PMID:
16411194
40.

Parent and physician perspectives on quality of care at the end of life in children with cancer.

Mack JW, Hilden JM, Watterson J, Moore C, Turner B, Grier HE, Weeks JC, Wolfe J.

J Clin Oncol. 2005 Dec 20;23(36):9155-61. Epub 2005 Sep 19.

PMID:
16172457
41.

Issues and challenges in palliative care for children with cancer.

Friedman DL, Hilden JM, Powaski K.

Curr Pain Headache Rep. 2005 Aug;9(4):249-55. Review.

PMID:
16004840
42.

Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group.

Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B, Felix CA, Davies SM, Slavin J, Potter JD, Blair CK, Reaman GH, Ross JA.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):651-5.

43.

Brain tumors in children.

Walter AW, Hilden JM.

Curr Oncol Rep. 2004 Nov;6(6):438-44. Review.

PMID:
15485612
44.

Issues and challenges in palliative care for children with cancer.

Friedman DL, Hilden JM, Powaski K.

Curr Oncol Rep. 2004 Nov;6(6):431-7.

PMID:
15485611
45.

Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA.

J Clin Oncol. 2004 Jul 15;22(14):2877-84.

PMID:
15254056
46.

Pediatric palliative care.

Himelstein BP, Hilden JM, Boldt AM, Weissman D.

N Engl J Med. 2004 Apr 22;350(17):1752-62. Review. No abstract available.

PMID:
15103002
47.

Tell the children.

Hilden JM, Watterson J, Chrastek J.

J Clin Oncol. 2003 May 1;21(9 Suppl):37s-39s. No abstract available.

PMID:
12743187
49.

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L.

Blood. 2002 Mar 15;99(6):1986-94. Erratum in: Blood 2002 Sep 1;100(5):1531.

50.

Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey.

Hilden JM, Emanuel EJ, Fairclough DL, Link MP, Foley KM, Clarridge BC, Schnipper LE, Mayer RJ.

J Clin Oncol. 2001 Jan 1;19(1):205-12.

PMID:
11134214

Supplemental Content

Loading ...
Support Center